Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EBITDA (2021 - 2025)

Senti Biosciences has reported EBITDA over the past 5 years, most recently at -$14.5 million for Q4 2025.

  • For Q4 2025, EBITDA fell 2271.64% year-over-year to -$14.5 million; the TTM value through Dec 2025 reached -$61.4 million, down 16.38%, while the annual FY2025 figure was -$61.4 million, 16.38% down from the prior year.
  • EBITDA for Q4 2025 was -$14.5 million at Senti Biosciences, up from -$18.1 million in the prior quarter.
  • Over five years, EBITDA peaked at -$1178.0 in Q1 2021 and troughed at -$28.9 million in Q3 2024.
  • A 5-year average of -$13.9 million and a median of -$14.3 million in 2025 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 1002276.91% in 2022 and later soared 96.74% in 2024.
  • Year by year, EBITDA stood at -$10.9 million in 2021, then plummeted by 66.99% to -$18.2 million in 2022, then decreased by 2.78% to -$18.7 million in 2023, then soared by 96.74% to -$610000.0 in 2024, then plummeted by 2271.64% to -$14.5 million in 2025.
  • Business Quant data shows EBITDA for SNTI at -$14.5 million in Q4 2025, -$18.1 million in Q3 2025, and -$14.7 million in Q2 2025.